H.C. Wainwright analyst Pat Trucchio adjusted the price target for Cybin Inc. (NYSE:CYBN) stock, lowering it to $150.00 from the previous $190.00 while maintaining a Buy rating on the company.

Mental health professionals reveal the hidden signs of anxiety disorders affecting millions of Americans, from mysterious ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand. | ...